Andere Sprachen IQ-AI Limited BOERSE MUENCHEN

Aktien

Markt geschlossen - BOERSE MUENCHEN Andere Börsenplätze 21:43:36 05.07.2024			% 5 Tage	% 1. Jan.
0.01 ^EUR	0.00%		-47.37%	-81.48%

25.06.	IQ-AI-Tochter eröffnet erweitertes Zugangsprogramm	AN
14.06.	IQ-AI-Team beginnt mit der Festlegung des Phase 2-Protokolls für orales Galliummaltolat	AN

IQ-AI subsidiary opens expanded access programme	25.06.
IQ-AI Says Brain Cancer Drug Delays Disease Progression in Early-stage Study	14.06.
IQ-AI team begins defining phase 2 protocol for oral gallium maltolate	14.06.
IQ-AI Ltd. Provides Update on Phase 1 Update	14.06.
Celadon ships to US; Oxford BioDynamics-Goodbody pact	23.05.
IQ-AI subsidiary gets second FDA rare paediatric disease designation	20.05.
IQ-AI's Imaging Biometrics Gets Second Rare Disease Designation for Drug Candidate	20.05.
Ingenta trades in line; Triple Point Social NAV up	17.05.
IQ-AI Unit Delivers Software to Insel Gruppe	17.05.
IQ-AI subsidiary gets rare paediatric disease designation FDA	10.05.
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	10.05.
EARNINGS AND TRADING: Trident Royalties swings to profit	02.05.
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	29.04.
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	29.04.
IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025	26.02.
IQ-AI's Broker Exercises Option to Buy Shares in Placing	26.02.
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	22.02.
IQ-AI shares sink on discounted placing fundraise	22.02.
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	09.02.
IQ-AI subsidiary asked by FDA to resubmit and modify application	09.02.

Keine Ergebnisse zu dieser Suche